These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 29569184)

  • 1. Mucosal Melanoma: a Literature Review.
    Yde SS; Sjoegren P; Heje M; Stolle LB
    Curr Oncol Rep; 2018 Mar; 20(3):28. PubMed ID: 29569184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy in melanoma: Recent advances and future directions.
    Franklin C; Livingstone E; Roesch A; Schilling B; Schadendorf D
    Eur J Surg Oncol; 2017 Mar; 43(3):604-611. PubMed ID: 27769635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melanoma and Immune Checkpoint Inhibitors.
    Furue M; Ito T; Wada N; Wada M; Kadono T; Uchi H
    Curr Oncol Rep; 2018 Mar; 20(3):29. PubMed ID: 29569208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
    Komatsubara KM; Carvajal RD
    Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (Neo)adjuvant systemic therapy for melanoma.
    van Zeijl MC; van den Eertwegh AJ; Haanen JB; Wouters MW
    Eur J Surg Oncol; 2017 Mar; 43(3):534-543. PubMed ID: 27453302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Not Available].
    Pagès C; Baroudjian B; Lebbé C
    Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R; Hall R; Kunk PR; Gaughan E; Dillon P; Slingluff CL; Rahma OE
    Immunotherapy; 2016 May; 8(5):583-600. PubMed ID: 27140411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional and systemic immunotherapy for metastatic melanoma.
    Luu C; Khushalani NI; Zager JS
    Expert Opin Biol Ther; 2016 Dec; 16(12):1491-1499. PubMed ID: 27602429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c-kit inhibitors.
    Papaspyrou G; Garbe C; Schadendorf D; Werner JA; Hauschild A; Egberts F
    Melanoma Res; 2011 Dec; 21(6):475-82. PubMed ID: 21897303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
    Ott PA; Hodi FS; Robert C
    Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melanoma Immunotherapy in the Elderly.
    Orloff M
    Curr Oncol Rep; 2018 Mar; 20(2):20. PubMed ID: 29500787
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue.
    Varricchi G; Marone G; Mercurio V; Galdiero MR; Bonaduce D; Tocchetti CG
    Curr Med Chem; 2018; 25(11):1327-1339. PubMed ID: 28403786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in immunotherapy for mucosal melanoma: harnessing immune checkpoint inhibitors for improved treatment outcomes.
    Shan Z; Liu F
    Front Immunol; 2024; 15():1441410. PubMed ID: 39234260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck.
    Thierauf J; Veit JA; Affolter A; Bergmann C; Grünow J; Laban S; Lennerz JK; Grünmüller L; Mauch C; Plinkert PK; Hess J; Hoffmann TK
    Melanoma Res; 2015 Dec; 25(6):503-9. PubMed ID: 26352784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single versus combination immunotherapy drug treatment in melanoma.
    Grimaldi AM; Marincola FM; Ascierto PA
    Expert Opin Biol Ther; 2016; 16(4):433-41. PubMed ID: 26642234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal melanoma of the head and neck: a systematic review of the literature.
    Lazarev S; Gupta V; Hu K; Harrison LB; Bakst R
    Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1108-18. PubMed ID: 25539369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of melanoma.
    Kee D; McArthur G
    Eur J Surg Oncol; 2017 Mar; 43(3):594-603. PubMed ID: 27514721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
    Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.